Response
Among the ICI+SBRT cohort, there were no CR, 2 PR, 8 SD and 6 PD at one month (Figure 1). Thirteen patients progressed at 6 months. The ICI monotherapy cohort had no CR or PR, 2 SD and 3 PD at one month, with 4 patients progressing by 6 months. There were no significant differences in PFS (p = 0.4), OS (p = 0.3) or in median PFS time for patients receiving ICI+SBRT (2.85 months; 95% CI: 1.7, 7.5) or ICI (1 month; 95% CI: 1 to unknown). Estimated six-month PFS probability was 0.19 (95% CI: 0.07 to 0.52) for patients receiving ICI+ SBRT and 0.2 (95% CI: 0.035 to 1) for patients receiving ICI. The median OS was 7 months (95% CI: 6 to 10) for patients receiving ICI+SBRT and 6 months (95% CI: 4 to unknown) for patients receiving ICI. Estimated six-month OS probability was 0.625 (95% CI: 0.43 to 0.91) for patients receiving ICI+SBRT and 0.4 (95% CI: 0.14 to 1) for patients receiving ICI. Kaplan-Meier plots for PFS and OS are shown in Figure 2.